Antenatal magnesium sulphate for preventing cerebral palsy: An economic evaluation of the impact of a quality improvement program.
Aust N Z J Obstet Gynaecol
; 62(1): 168-171, 2022 02.
Article
em En
| MEDLINE
| ID: mdl-34843629
ABSTRACT
Previous work demonstrated that implementing a quality improvement (QI) program improves the uptake of guideline-recommended antenatal magnesium sulphate, a critical intervention known to reduce cerebral palsy risk. Here we estimate potential cost savings attributable to the improved uptake. By expanding coverage from 63 to 83% of eligible women, we estimated that five children potentially would not have received a diagnosis of cerebral palsy, a potential cost saving of $AU4.8 million in lifetime healthcare costs. Our findings strengthen the case for embedding QI approaches in perinatal care to reduce the incidence of cerebral palsy.
Palavras-chave
Texto completo:
1
Temas:
ECOS
/
Aspectos_gerais
/
Avaliacao_economica
Bases de dados:
MEDLINE
Assunto principal:
Paralisia Cerebral
/
Fármacos Neuroprotetores
/
Nascimento Prematuro
Tipo de estudo:
Evaluation_studies
/
Guideline
/
Health_economic_evaluation
Aspecto:
Implementation_research
Limite:
Child
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
Aust N Z J Obstet Gynaecol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Austrália